Login / Signup

Drug screening identifies tazarotene and bexarotene as therapeutic agents in multiple sulfatase deficiency.

Lars SchlotawaKarolina TykaMatthias KettwigRebecca C Ahrens-NicklasMatthias G J BaudTea BerulavaNicola Brunetti-PierriAlyssa L GagneZackary M HerbstJean A MaguireJlenia MonfregolaTonatiuh Pena CentenoKarthikeyan RadhakrishnanSophie SchröderElisa A WaxmanAndrea BalabioThomas DierksAndre FischerDeborah L FrenchMichael H GelbJutta Gärtner
Published in: EMBO molecular medicine (2023)
Multiple sulfatase deficiency (MSD, MIM #272200) results from pathogenic variants in the SUMF1 gene that impair proper function of the formylglycine-generating enzyme (FGE). FGE is essential for the posttranslational activation of cellular sulfatases. MSD patients display reduced or absent sulfatase activities and, as a result, clinical signs of single sulfatase disorders in a unique combination. Up to date therapeutic options for MSD are limited and mostly palliative. We performed a screen of FDA-approved drugs using immortalized MSD patient fibroblasts. Recovery of arylsulfatase A activity served as the primary readout. Subsequent analysis confirmed that treatment of primary MSD fibroblasts with tazarotene and bexarotene, two retinoids, led to a correction of MSD pathophysiology. Upon treatment, sulfatase activities increased in a dose- and time-dependent manner, reduced glycosaminoglycan content decreased and lysosomal position and size normalized. Treatment of MSD patient derived induced pluripotent stem cells (iPSC) differentiated into neuronal progenitor cells (NPC) resulted in a positive treatment response. Tazarotene and bexarotene act to ultimately increase the stability of FGE variants. The results lay the basis for future research on the development of a first therapeutic option for MSD patients.
Keyphrases